Syndax Q3 Revenue Jumps 82% to $83.3M; CFO Goldan Retires, Ondrey Named
SNDX is trading near its 52-week low of $12.795 (0.8% above the low).
Summary
Third-quarter revenue of $83.3 million, up 82% year-over-year, and a narrower $49.4 million net loss headlined Syndax's results, alongside news that CFO Keith Goldan will retire and Aaron Ondrey will succeed him effective November 9, 2026.
Key Events · Earnings and Guidance · SNDX
-
Q3 Revenue Grows 82% to $83.3M
Total revenue reached $83.3 million versus $45.9 million a year ago, comprising $60.7 million of Revuforj product revenue and $22.6 million of Niktimvo collaboration revenue.
-
Net Loss Narrows to $49.4M
The net loss of $49.4 million, or $0.55 per share, improved from $60.7 million, or $0.70 per share, in the prior-year quarter; R&D rose to $67.5 million while SG&A fell to $43.7 million.
-
CFO Transition Effective November 9
Keith Goldan retires as CFO and treasurer effective November 9, 2026 and will serve as an advisor; Aaron Ondrey joins as CFO on the same date with a $543,000 base salary, 45% target bonus and a 270,000-share option grant.
-
IPF Trial Misses Primary Endpoint
The MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint, and Syndax does not plan further development in IPF; ongoing chronic GVHD trials are unaffected.
Analysis · SNDX · Life Sciences
The commercial engine is delivering: total revenue of $83.3 million climbed 82% year-over-year, powered by Revuforj at $60.7 million (+90%) and Niktimvo collaboration revenue of $22.6 million. Net loss narrowed to $49.4 million from $60.7 million a year ago, and with $551.1 million of cash alongside maintained expense guidance of roughly $400 million, management's path to profitability stays intact. Set against that, the CFO handoff is a managed transition rather than a disruption — Keith Goldan retires November 9 and Aaron Ondrey, a former Rocket Pharmaceuticals and Mirati CFO, steps in — though it lands mid-commercial ramp. The offsetting negative is the MAXPIRe failure in IPF, which removes an axatilimab expansion path but leaves the approved chronic GVHD franchise untouched.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNDX was trading at $12.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $12.80 to $25.59. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.